BioXcel Therapeutics Announces Proposed Public Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/25/2026
- S&P 500 ends marginally lower as investors focus on US-Iran war
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oil gains on little sign of progress in US-Iran talks
- S&P 500 history shows strong gains across Fed hiking cycles: BCA
- JPMorgan upgrades CoreWeave on stronger compute pricing
- Bloom Energy falls as Oracle invokes force majeure on AI project
- Akamai signs $11.6B deal with Anthropic, up to $20B potential
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oracle Sends Force Majeure Notice Over New Mexico Data Center - Bloomberg
- US and Iran discuss phased deal to reopen Hormuz and end US blockade, sources say
BioXcel Therapeutics (BTAI) surges on FDA fast track designation for BXCL701
February 12, 2024 7:53 AM ESTBioXcel Therapeutics (NASDAQ: BTAI) shares rallied more than 24% premarket after the U.S. Food and Drug Administration (FDA) designated a Fast Track development program for BXCL701.
More specifically, the Fast Track designation is for the investigation of BXCL701 in combination with a... More
